Cargando…
Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis
Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic SCT (HSCT) is recognized as a new-onset obstructive lung defect (OLD) in pulmonary function testing and is related to pulmonary chronic GVHD. Little is known about the different phenotypes of patients with BOS and their outcomes....
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091913/ https://www.ncbi.nlm.nih.gov/pubmed/23208317 http://dx.doi.org/10.1038/bmt.2012.241 |
_version_ | 1783510078105583616 |
---|---|
author | Bergeron, A Godet, C Chevret, S Lorillon, G Peffault de Latour, R de Revel, T Robin, M Ribaud, P Socié, G Tazi, A |
author_facet | Bergeron, A Godet, C Chevret, S Lorillon, G Peffault de Latour, R de Revel, T Robin, M Ribaud, P Socié, G Tazi, A |
author_sort | Bergeron, A |
collection | PubMed |
description | Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic SCT (HSCT) is recognized as a new-onset obstructive lung defect (OLD) in pulmonary function testing and is related to pulmonary chronic GVHD. Little is known about the different phenotypes of patients with BOS and their outcomes. We reviewed the data of all allogeneic HSCT recipients referred to our pulmonary department for a non-infectious bronchial disease between 1999 and 2010. We identified 103 patients (BOS (n=77), asthma (n=11) and chronic bronchitis (n=15)). In patients with BOS, we identified two functional phenotypes: a typical OLD, that is, forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio <0.7 (n=53), and an atypical OLD with a concomitant decrease in the FEV1 <80% and FVC <80% predicted with a normal total lung capacity (n=24). The typical OLD was characterized by more severe FEV1 and fewer centrilobular nodules on the computed tomography scan. The FEV1 was not significantly affected during the follow-up, regardless of the phenotype. In addition to acute and extensive chronic GVHD, only the occurrence of BOS soon after transplantation and the intentional treatment of BOS with steroids were associated with a poor survival. The determination of patient subgroups should be explored to improve the management of this condition. |
format | Online Article Text |
id | pubmed-7091913 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-70919132020-03-24 Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis Bergeron, A Godet, C Chevret, S Lorillon, G Peffault de Latour, R de Revel, T Robin, M Ribaud, P Socié, G Tazi, A Bone Marrow Transplant Article Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic SCT (HSCT) is recognized as a new-onset obstructive lung defect (OLD) in pulmonary function testing and is related to pulmonary chronic GVHD. Little is known about the different phenotypes of patients with BOS and their outcomes. We reviewed the data of all allogeneic HSCT recipients referred to our pulmonary department for a non-infectious bronchial disease between 1999 and 2010. We identified 103 patients (BOS (n=77), asthma (n=11) and chronic bronchitis (n=15)). In patients with BOS, we identified two functional phenotypes: a typical OLD, that is, forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio <0.7 (n=53), and an atypical OLD with a concomitant decrease in the FEV1 <80% and FVC <80% predicted with a normal total lung capacity (n=24). The typical OLD was characterized by more severe FEV1 and fewer centrilobular nodules on the computed tomography scan. The FEV1 was not significantly affected during the follow-up, regardless of the phenotype. In addition to acute and extensive chronic GVHD, only the occurrence of BOS soon after transplantation and the intentional treatment of BOS with steroids were associated with a poor survival. The determination of patient subgroups should be explored to improve the management of this condition. Nature Publishing Group UK 2012-12-03 2013 /pmc/articles/PMC7091913/ /pubmed/23208317 http://dx.doi.org/10.1038/bmt.2012.241 Text en © Macmillan Publishers Limited 2013 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Bergeron, A Godet, C Chevret, S Lorillon, G Peffault de Latour, R de Revel, T Robin, M Ribaud, P Socié, G Tazi, A Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis |
title | Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis |
title_full | Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis |
title_fullStr | Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis |
title_full_unstemmed | Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis |
title_short | Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis |
title_sort | bronchiolitis obliterans syndrome after allogeneic hematopoietic sct: phenotypes and prognosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091913/ https://www.ncbi.nlm.nih.gov/pubmed/23208317 http://dx.doi.org/10.1038/bmt.2012.241 |
work_keys_str_mv | AT bergerona bronchiolitisobliteranssyndromeafterallogeneichematopoieticsctphenotypesandprognosis AT godetc bronchiolitisobliteranssyndromeafterallogeneichematopoieticsctphenotypesandprognosis AT chevrets bronchiolitisobliteranssyndromeafterallogeneichematopoieticsctphenotypesandprognosis AT lorillong bronchiolitisobliteranssyndromeafterallogeneichematopoieticsctphenotypesandprognosis AT peffaultdelatourr bronchiolitisobliteranssyndromeafterallogeneichematopoieticsctphenotypesandprognosis AT derevelt bronchiolitisobliteranssyndromeafterallogeneichematopoieticsctphenotypesandprognosis AT robinm bronchiolitisobliteranssyndromeafterallogeneichematopoieticsctphenotypesandprognosis AT ribaudp bronchiolitisobliteranssyndromeafterallogeneichematopoieticsctphenotypesandprognosis AT socieg bronchiolitisobliteranssyndromeafterallogeneichematopoieticsctphenotypesandprognosis AT tazia bronchiolitisobliteranssyndromeafterallogeneichematopoieticsctphenotypesandprognosis |